ARGX
705.592 EUR
-0.54%
Today
-0.51%
1D
Last seen at Wed, 25 Feb 2026 14:18:00 GMT+3
Market is open
Sun
Closed
Mon
10:01 AM ~ 6:30 PM
Tue
10:01 AM ~ 6:30 PM
Wed
10:01 AM ~ 6:30 PM
Thu
10:01 AM ~ 6:30 PM
Fri
10:01 AM ~ 6:30 PM
Sat
Closed
Performance
1 Day
- 0.51 %
1 Week
- 0.28 %
1 Month
+ 2.05 %
3 Month
- 9.22 %
6 Month
+ 20.15 %
1 Year
+ 18.06 %
Information
Name
Argenx Leveraged ( BE )
Currency
EUR
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0137%
Overnight Fees Sell
-0.0030%
Market Cap
47.77B
Avg Daily Volume
65.52K
52 Week High
810 EUR
52 Week Low
456.6 EUR
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01370% | $(0.137) |
| SELLS | -0.00300% | $(0.030) |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Top News
argenx to Present at TD Cowen 46th Annual Healthcare Conference
tradingview.com
2d ago
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
tradingview.com
6d ago
After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones
tradingview.com
1mo ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
